Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Novartis
Gustave Roussy, Cancer Campus, Grand Paris
Repare Therapeutics
Yale University
Suzhou Zanrong Pharma Limited
Centre Leon Berard
Peter MacCallum Cancer Centre, Australia
Guangzhou JOYO Pharma Co., Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Merck Sharp & Dohme LLC
Bridge Biotherapeutics, Inc.
Shenzhen TargetRx Co., Ltd.
University of Jena
ESSA Pharmaceuticals
Fudan University
MedPacto, Inc.
Oblato, Inc.
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
EMD Serono
Affiliated Hospital of Qinghai University
Takeda
Bayer
Niguarda Hospital
Medical College of Wisconsin
Zai Lab (Hong Kong), Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Eli Lilly and Company
Arog Pharmaceuticals, Inc.
Grupo Español de Tumores Huérfanos e Infrecuentes
TetraLogic Pharmaceuticals
Bayer
Incyte Corporation
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University of Kansas Medical Center
University of Kansas Medical Center